Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan for post-transplant recurrent C3G or IC-MPGN
NL-OMON60608Phase 2Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Dec 2021
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegcetacoplan in Complement 3 glomerulopathy (C3G) and Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) (2 arms), sponsored by Apellis Pharmaceuticals. Primary endpoint: Proportion of subjects with reduction in C3c staining on renal biopsy after 12 weeks. Started Dec 2021; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
Complement 3 glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Beyond the preview
Go deeper on NL-OMON60608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60608.